OXS-3550 for liquid tumors. The TRiKE platform has shown promising in vivo data compared to BiKEs . (The addition of Il-15 created NK cell proliferation resulting in 60-70% remission vs 30- 50% for BiKE)
OXS-4550 Again using the TRiKE platform In Vivo data isn't yet, however Dr. Miller assured me in the email that they've made significant progress with it.
OXS-4235 There's a chance (albeit slim) that this Multiple Myeloma drugs enters the clinic this year
News 
Market Data 
Discover 
